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Abstract: New simple spectroﬂ  uorimetric method with enhanced sensitivity has been developed and validated for the 
determination of the antidepressant paroxetine (PXT) in its dosage forms and plasma. The method was based on nucleophilic 
substitution reaction of PXT with 4-chloro-7-nitrobenzo-2-oxa-1,3-diazole in an alkaline medium (pH 8) to form a highly 
ﬂ  uorescent derivative that was measured at 545 nm after excitation at 490 nm. The factors affecting the reaction was carefully 
studied and optimized. The kinetics of the reaction was investigated, and the reaction mechanism was presented. Under the 
optimized conditions, linear relationship with good correlation coefﬁ  cient (0.9993) was found between the ﬂ  uorescence 
intensity and PXT concentration in the range of 80–800 ng ml
−1. The limits of detection and quantitation for the method 
were 25 and 77 ng ml
−1, respectively. The precision of the method was satisfactory; the values of relative standard deviations 
did not exceed 3%. The proposed method was successfully applied to the determination of PXT in its pharmaceutical tablets 
with good accuracy; the recovery values were 100.2 ± 1.61%. The results obtained by the proposed method were comparable 
with those obtained by the ofﬁ  cial method. The proposed method is superior to the previously reported spectroﬂ  uorimetric 
method for determination of PXT in terms of its higher sensitivity and wider linear range. The high sensitivity of the method 
allowed its successful application to the analysis of PXT in spiked human plasma. The proposed method is practical and 
valuable for its routine application in quality control and clinical laboratories for analysis of PXT.
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Introduction
Paroxetine (PXT) is a new generation antidepressant drug. It exerts its antidepressant effect through a 
selective inhibition for the reuptake of the neurotransmitter serotonin by the presynaptic receptors. PXT 
is comparable to the tricyclic antidepressants in their clinical efﬁ  cacy, however PXT is safer and has 
greater acceptance by the patients [1]. It is also prescribed in the treatment of related disorders, such as 
obsessive-compulsive disorder, panic ﬁ  ts, social phobia, and post-traumatic stress [2]. PXT is devoid 
of sedative effect and remarkably safe in overdose. PXT takes 5.2 hours to reach the peak, with extended 
half-life (21 hours) that allowed the introduction of formulations for once-daily dosing [3]. These 
combined qualities made PXT the most widely prescribed antidepressants [4].
The methods reported for quantitative determination of PXT in dosage forms and/or biological ﬂ  uids 
include voltammetry [5,6], densitometry [7,8], high performance liquid chromatography [9–14], gas 
chromatography [15–17], capillary electrophoresis [18], spectrophotometry [19–21], and 
spectroﬂ  uorimetry [22]. The chromatographic and electrophoretic methods offered the required sensitivity 
and selectivity for the analysis of PXT in biological ﬂ  uids, however their sophisticated instrumentation, 
tedious sample clean-up procedures, and high analysis cost limited their routine use for determination 
of PXT in quality control and clinical laboratories. Spectrophotometric methods, although the inherent 
simplicity of the technique, were time-consuming as they involved laborious multiple extraction steps 
and long reaction time [21], and they had inadequate sensitivity for determination of PXT in biological 
ﬂ  uids.
Spectroﬂ  uorimetry is considered a sensitive and simple technique. Only one spectroﬂ  uorimetric 
method has been described for determination of PXT based on measuring its native ﬂ  uorescence [22], 
with limit of quantitation of 50 ng ml
−1. Although the authors claimed the applicability of the method 
for determination of PXT in spiked human plasma based on the recovery of spiked PXT, however the 
spiked concentrations (100–400 ng ml
−1 ) were higher than the reported maximum plasma level of PXT 146
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(10–30 ng ml
−1) [23], in addition to the poor 
recovery (77.7%) obtained by this method. For 
these reasons, the development of new alternative 
more sensitive spectroﬂ  uorimetric method for the 
determination of PXT was very essential.
The present study describes the development 
and validation of a new simple spectroﬂ  uorimetric 
method with enhanced sensitivity for determination 
of PXT in dosage forms and plasma with a limit of 
detection of 25 ng ml
−1. The method was based on 
the derivatization of PXT with 4-chloro-7-nitoben-
zofurazan (NBD-Cl) reagent to produce a ﬂ  uorescent 
derivative. The induced ﬂ  uorescence intensity was 
measured at 545 nm after excitation at 490 nm, and 
correlated with the PXT concentrations.
Experimental
Apparatus
FP-6200 ﬂ  uorometer (JASCO Co. Ltd., Kyoto, 
Japan), with 1-cm quartz cells was used for all 
measurements. The slit width of both the excitation 
and emission monochromators was set at 1.5 nm. 
The calibration and linearity of the instrument were 
frequently checked with standard quinine sulphate 
(0.01 μg ml
−1). Wavelength calibration was 
performed by measuring λexcitation 275 nm and 
λemission 430 nm; no variation in the wavelength 
was observed. pH meter, Model 350 (Bibby 
Scientiﬁ  c Ltd., T/As Jenway, Essex, England). 
MLW type thermostatically controlled water bath 
(Memmert GmbH, Co. Schwa bach, Germany).
Reagents and materials
Paroxetine hydrochloride (PXT; SmithKline 
Beecham Pharmaceuticals, Bentford, England) was 
obtained and used as received; its purity was 99.8 ± 
1.45%. A solution of 0.2% (w/v) of 4-chloro-7-
nitrobenzo-2-oxa-1,3-diazole (NBD-Cl; Sigma 
Chemical Co., St. Louis, U.S.A.) was freshly 
prepared by dissolving 100 mg in 50 ml acetone. 
Clark and Lubs buffer solution of pH 8 was prepared 
by mixing 50 ml of 0.2 M aqueous solution of boric 
acid and KCl (1 liter contains 12.368 g of boric acid 
and 14.90 g of KCl) with 0.2 M NaOH in 200 ml 
standard ﬂ  ask [24], and adjusted by pH meter. 
Seroxate tablets (SmithKline Beecham Pharmaceu-
ticals) are labeled to contain 20 mg PXT per tablet. 
Human plasma samples were collected from normal 
healthy volunteer at King Khaled University 
Hospital (Riyadh, Saudi Arabia), and they were 
stored in deep-freezer at −20 °C until analysis. 
Double distilled water was obtained through 
WSC-85 water purification system (Hamilton 
Laboratory Glass Ltd., Kent, U.S.A.), and used 
throughout the work. All solvents and materials used 
throughout this study were of analytical grade.
Preparation of standard and sample 
solutions
Paroxetine hydrochloride (PXT) standard 
solution
An accurately weighed amount (50 mg) of PXT was 
quantitatively transferred into a 25-ml calibrated 
ﬂ  ask, dissolved in 20 ml distilled water, completed 
to volume with the same solvent to obtain a stock 
solution of 2 mg ml
−1. This stock solution was 
further diluted with water to obtain working solu-
tions in the ranges of 800–8000 ng ml
−1.
Tablets sample solution
Twenty tablets were weighed, and ﬁ  nely powdered. 
An accurately weighed quantity of the powdered 
tablets equivalent to 100 mg of PXT was trans-
ferred into a 100-ml calibrated ﬂ  ask, and dissolved 
in about 40 ml of distilled water. The contents of 
the ﬂ  ask were swirled, sonicated for 5 min, and 
then completed to volume with water. The contents 
were mixed well and ﬁ  ltered rejecting the ﬁ  rst 
portion of the ﬁ  ltrate. The prepared solution was 
diluted quantitatively with distilled water to obtain 
a suitable concentration for the analysis.
Plasma samples
Aliquots of 1 ml of PXT solution (800–8000 ng ml
−1) 
were dispensed into test tubes. A 1 ml of drug-free 
plasma and 2 ml of acetonitrile was added. After 
vortexing for 3 min, the tube was centrifuged at 
4500 rpm for 20 min. The mixture was rendered 
alkaline with 0.1 M NaOH and then extracted three 
times with 3 × 1.5 ml hexane:isoamyl alcohol 
(99:1, v/v). The extract was transferred to another 
5 ml tube and evaporated to dryness under stream 
of nitrogen gas at 40 °C. The residue was dissolved 
in 1 ml acetone and used for analysis.
General recommended procedure
Accurately measured aliquots of PXT solution 
containing 800–8000 ng ml
−1 were transferred into 147
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separate 10-ml calibrated ﬂ  asks. One milliliter of 
Clark and Lubs buffer solution (pH 8 ± 0.2) was 
added followed by 1 ml of NBD-Cl solution 
(0.2%, w/v). The reaction solution was allowed to 
proceed at 40 ± 5 °C for 30 min. After cooling, the 
reaction mixture was acidiﬁ  ed by adding 1 ml of 
0.1 M HCl, and completed to volume with acetone. 
The ﬂ  uorescence intensity of the resulting solution 
was measured at 490 nm after excitation at 545 nm 
against reagent blanks prepared in the same manner 
with 1 ml water instead of 1 ml sample solution.
Determination of the stoichiometric 
ratio of the reaction
In the limiting logarithmic method [25], two sets of 
experiments were carried out employing the general 
recommended procedures described above. The ﬁ  rst 
set of experiments were carried using increasing 
NBD-Cl concentrations (5 × 10
–5–5 × 10
–4 M) at 
ﬁ  xed PXT concentration (1.37 × 10
–6 M). The second 
set of experiments were carried using increasing PXT 
concentrations (3.28 × 10
–7 –2.19 × 10
–6 M) at ﬁ  xed 
NBD-Cl concentration (1 × 10
–3 M). The logarithms 
of the obtained ﬂ  uorescence intensities were plotted 
as a function of the logarithms of the NBD-Cl and 
PXT concentration in the ﬁ  rst and second sets of 
experiments, respectively. The slopes of the ﬁ  tting 
lines in both sets of experiments were calculated.
Results and Discussion
Strategy for assay development 
and spectral characteristics
PXT exhibits weak native fluorescence, thus 
its derivatization with fluorogenic reagent 
was necessary to increase its detectability and 
ultimately the sensitivity for its spectroﬂ  uorimetric 
determination. NBD-Cl has been used as a 
derivatizing reagent in the spectrofluorimetric 
determination of many pharmaceutical amines 
[26–29]. It forms highly ﬂ  uorescent derivatives 
with amines using relatively mild reaction 
conditions. The reaction of NBD-Cl with PXT has 
not been investigated yet. Therefore, the present 
study was devoted to investigate the reaction 
between NBD-Cl and PXT (being amine), and 
employment the reaction in the development of 
sensitive and simple spectroﬂ  uorimetric method for 
determination of  PXT in dosage forms and plasma. 
Owing to the presence of labile chloride in the 
chemical structure of NBD-Cl, a daily fresh solution 
was prepared and tested in the present study. It was 
found that PXT reacts with NBD-Cl and forms a 
yellow fluorescent derivative. This derivative 
exhibited maximum ﬂ  uorescence intensity (λem) at 
545 nm after its excitation at maximum wavelength 
(λex) at 490 nm. The excitation and emission spec-
tra for the reaction product of PXT with NBD-Cl 
are given in Figure. 1.
Optimization of reaction variables
Effect of NBD-Cl Concentration
The effect of NBD-Cl concentration on its reaction 
with PXT revealed that the reaction was dependent 
on NBD-Cl concentration as the fluorescence 
intensity (FI) of the reaction solution increased as 
the NBD-Cl concentration increased (Fig. 2). The 
highest readings were attained at NBD-Cl concentration 
of 0.1% (w/v). At higher concentrations of NBD-Cl 
up to 0.4%, the fluorescence intensity was not 
affected. For more precise readings, further 
experiments were carried out using 0.2%.
Effect of temperature and time
In order to determine the optimum temperature and 
time required for completion the reaction, the 
derivatization reaction was carried out at room tem-
perature (25 ± 5 °C) and the induced FI values were 
monitored at different time intervals. It was found 
that the reaction was very slow, and did not go to 
completion in reasonable time; it required more than 
1 hour (Fig. 3). Therefore, investigations were carried 
out at varying elevated temperatures (40–70 °C), and 
the intensities of the induced fluorescence were 
monitored for 60 min. The optimum conditions were 
considered as the conditions at which the high 
FI values, high reproducible results, and comfortable 
measurements (wide plateau region on the FI-time 
curve) could be obtained. The results indicated that 
the reaction was dependent on temperature, and the 
optimum condition was achieved by heating at 40 °C 
for 30 min. At higher temperatures, the maximum FI 
was obtained in shorter times (∼10 min), however 
rapid progressive decrease in the readings was 
observed as the reaction time increased. This was 
probably attributed to the degradation of the reagent 
at high temperature. This observation was coincident 
with the results that have been previously reported 
by Aktas et al. [30].148
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Figure 1. Excitation (1) and emission (2) spectra of the reaction product of PXT (300 ng ml
−1) with NBD-Cl (0.2%, w/v).
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Figure 2. Effect of NBD-Cl concentration (•) and pH (♦) on the ﬂ  uorescence intensity of the product of the reaction of PXT (600 ng ml
−1) 
and NBD-Cl.149
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Figure 3. Effect of time on the reaction of NBD-Cl (0.2%, w/v) with PXT (600 ng ml
−1) at different temperatures. RFI is the relative ﬂ  uorescence 
intensity.
Effect of pH
In order to generate the nucleophile from PXT, 
the reaction should be carried out in alkaline 
medium. Different alkaline buffer systems 
(borate, phosphate, and carbonate) having the 
same pH value (8) were tested. The highest FI 
was obtained when the reaction was carried out 
in Clark and Lubs buffer. With other buffers, 
either precipitation of white colloid occurred 
upon addition of NBD-Cl reagent solution, non 
reproducible results, and/or weak sensitivities 
were observed.
The effect of pH on the reaction was studied 
by carrying out the reaction in Clark and Lubs 
buffer solution of pH 5–9.5. The results indicated 
that the FI increased as the pH increased and 
maximum readings were obtained at pH 8 ± 0.2 
(Fig. 2). This increase in the FI with the pH was 
possibly due to the conversion of amino group 
of PXT from the HCl salt form (in acidic pH 
values) to the free amino group as the pH turns 
alkaline. This facilitates the nucleophilic 
substitution reaction. At pH above 8.2, sharp 
decrease in the readings occurred. This was 
attributed probably to the increase in the amount 
of hydroxide ion that holds back the condensation 
reaction between PXT and NBD-Cl. In order to 
keep the high sensitivity for determination of 
PXT, the subsequent experiments were carried 
out at pH 8 ± 0.2.
Effect of HCl concentration
Under the above mentioned conditions, signiﬁ  -
cantly high ﬂ  uorescence backgrounds were also 
observed. This was attributed to the hydrolysis of 
NBD-Cl to the corresponding hydroxy derivative 
namely, 4-hydroxy-7-nitrobenzo-2-oxa-1,3-diazole 
(NBD-OH) [31]. The ﬂ  uorescence of NBD-OH was 
found to be quenched by decreasing the pH of the 
reaction medium to less than one [32]. Therefore 
acidification of the reaction mixture prior to 
measurement of the FI was necessary to remarkably 
decrease the background ﬂ  uorescence. Meanwhile, 
the reaction product was not affected, thus the 
sensitivity was ultimately increased. The concentra-
tion of HCl required for acidiﬁ  cation was found to 
be 0.01 M in the ﬁ  nal assay solutions (i.e. 1 ml of 
0.1 M).
Effect of diluting solvent
Upon diluting the reaction with water, colloids 
were obtained indicating the incomplete solubility 
of PXT-NBD in water. Therefore, water could not 
be used for dilution. In order to select the most 
appropriate organic solvent for diluting the reaction 
solution, different solvents were tested: methanol, 
ethanol, isopropanol, acetone, and acetonitrile. The 
highest readings were obtained when acetone was 
used. Therefore, acetone was used for diluting the 
reaction mixture in the subsequent experiments.150
Darwish et al
Analytical Chemistry Insights 2008:3 
Stability of the ﬂ  uorescent derivative
The effect of time on the stability of the PXT-NBD 
ﬂ  uorescent derivative was studied by following the 
FI of the reaction solution (after dilution) at different 
time intervals. It was found that the FI values 
remain constant for at least 1 hour. This allowed 
the processing of large batches of samples, and their 
comfortable measurements with convenience. This 
increased the convenience of the method as well as 
made it applicable for large number of samples.
A summary for the optimization of the variables 
affecting the reaction of PXT with NBD-Cl is given 
in Table 1.
Stoichiometry and kinetics 
of the reaction
The stoichiometry of the reaction between PXT and 
NBD-Cl was investigated by limiting logarithmic 
method [25]. Two straight lines with comparable 
slopes (0.8035 and 0.9405) were obtained indicating 
the 1:1 ratio for the reactions. Based on this ratio, 
the reaction pathway between PXT and NBD-Cl 
was postulated to proceed as shown in Fig. 4.
Under the optimum conditions (Table 1), the 
ﬂ  uorescence intensity-time curves for the reaction 
at varying PXT concentrations (2.73 × 10
–7–
10.93 × 10
–7 M) with a fixed concentration 
of  NBD-Cl (1 × 10
–3 M) were generated. The initial 
reaction rates (k) were determined from the slopes 
of these curves (from 0–25 min). The logarithms of 
the reaction rates (Log k) were plotted as a function 
of logarithms of PXT concentrations (log C). The 
regression analysis for the values was performed 
by ﬁ  tting the data to the following equation:
Log k = log k′ + n log C
where k is reaction rate, k′ is the rate constant, C is 
the molar concentration of PXT, and n (slope of 
the regression line) is the order of the reaction. 
A straight line with slope values of 1.02527 (≈1) 
was obtained conﬁ  rming that the reaction was ﬁ  rst 
order. However under the optimized reaction 
conditions, the concentration of NBD-Cl was in 
much more excess than that of PXT in the reaction 
solution. Therefore, the reaction was regarded as 
a pseudo-ﬁ  rst order reaction.
The apparent rate constant 
and activation energy
The ﬂ  uorescence intensity-time curves at different 
temperatures (25, 40, 50, 60, and 70 °C) were 
generated using fixed concentration of PXT 
(8.2 × 10
−7 M) and NBD-Cl (1 × 10
−3 M). The 
reaction time was set at maximum 10 min, before 
the decrease of the FI occurs at high temperatures 
(Fig. 3). From these curves the apparent rate 
constants were calculated. The activation energy, 
deﬁ  ned as the minimum kinetic energy that a 
molecule possess in order to undergo a reaction, 
was determined using Arrhenius equation [33]:
Log k = log A–Ea/2.303 RT
where k is the apparent rate constant, A is the 
frequency factor, Ea is the activation energy, T is the 
absolute temperature (°C + 273), and R is the gas 
constant (1.987 calories degree
–1 mole
–1). The values 
of log k were plotted as a function of 1/T. Straight 
line with slope value of –2.2843 (= –Ea/2.303 R) 
was obtained (Fig. 5). From these data, the 
activation energy was calculated and found to be 
43.73 k joule mole
–1. This low activation energy 
Table 1. Optimization of variables affecting the reaction of PXT with NBD-Cl.
Variable Studied range Optimum condition
NBD-Cl (%, w/v) 0.01–0.5 0.2
pH 5–9.5 8 ± 0.2
Temperature (°C) 25–70 40
Time (min) 5–60 30
HCl (M) 0.02–0.5 0.1
Solvent Different
a Acetone
Stability of PXT-NBD (min) 10–60 60
aSolvents tested: methanol, ethanol, isopropanol, acetone, and acetonitrile.
bThe stability of the PXT-NBD was studied after dilution of the reaction solution.151
New spectroﬂ  uorimetric method with enhanced sensitivity for determination of paroxetine in dosage forms and plasma
Analytical Chemistry Insights 2008:3 
PXT NBD-Cl
pH = 8 ± ± ± ± 0.2
Fluorescent PXT-NBD
(λex = 490 nm, λem = 545 nm)
+
N
O
N
Cl NO2
O
O ON H
F
O
O ON
F
NO2
N
N
O
Figure 4. Scheme for the reaction pathway of PXT with NBD-Cl.
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Figure 5. Arrhenius plot for the reaction of NBD-Cl and PXT. T and K are the absolute temperature and the apparent rate constant, respectively. 
[PXT] is 8.2 × 10
−7 M and [NBD-Cl] is 1 × 10
−3 M.152
Darwish et al
Analytical Chemistry Insights 2008:3 
explained that the nucleophilic substitution 
reactions between PXT and NBD-Cl could be 
easily takes place under mild conditions, and 
NBD-Cl could be used as a useful reagent in the 
spectroﬂ  uorimetric determination of PXT.
Validation of the method
Calibration and sensitivity
Under the optimum conditions (Table 1), calibration 
curve for the determination of PXT by its reaction 
with NBD-Cl was constructed by plotting the FI 
as a function of the corresponding PXT concentration 
(Fig. 6). The regression equation for the results 
was: FI = a + b C , where FI is the ﬂ  uorescence 
intensity, C is the concentration of PXT in ng 
ml
–1. Linear relationship with small intercept and 
good correlation coefﬁ  cient (0.9993) was obtained 
in the range of 80–800 ng ml
–1. The limit of 
detection (LOD) and limit of quantitation (LOQ) 
were determined according to The International 
Conference of Harmonization (ICH) guidelines for 
validation of analytical procedures [34]. The LOD 
and LOQ values were found to be 25 and 77 ng ml
–1, 
respectively. The parameters for the analytical 
performance of the proposed spectroﬂ  uorimetric 
method are summarized in Table 2.
Reproducibility
The reproducibility of the proposed method was 
determined by replicate analysis of ﬁ  ve separate 
solution of the working standard. The method gave 
satisfactory results; RSD was 3% indicating its 
good reproducibility. This precision level is ade-
quate for the precision and routine analysis of 
PXT.
Accuracy and speciﬁ  city
The analytical recovery of the proposed spectro-
ﬂ  uorimetric method was studied for added PXT 
concentrations, and the values were 97.8–101.2 ± 
1.04–1.85% (Table 3), indicating the accuracy of 
the proposed method. The specificity of the 
method was evaluated by investigating the inter-
ference liabilities from the common excipients 
that might be added during pharmaceutical 
250
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Figure 6. Calibration curve for spectroﬂ  uorimetric determination of PXT based on its reaction with NBD-Cl reagent. RFI is the relative 
ﬂ  uorescence intensity.153
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was calculated each time. It was found that 
variation in the NBD-Cl concentrations (0.15%–
0.25%, w/v), temperature (optimum ± 5 °C), and 
time (optimum ± 5 min) did not signiﬁ  cantly affect 
the procedures; recovery values were 95.5–102.4, 
and the RSD values did not exceed 4%. The most 
critical factor affecting the results was the pH that 
should be adjusted to be in the range of 8 ± 0.2. 
Ruggedness was also tested by applying the 
method to the assay of PXT using the same opera-
tional conditions but using two different instru-
ments at two different laboratories and different 
elapsed time. Results obtained from lab-to-lab and 
day-to-day variations were reproducible, as the 
RSD did not exceed 4%.
Applications of the method
It is evident from the above-mentioned results that 
the proposed method gave satisfactory results with 
PXT in its bulk. Thus its pharmaceutical dosage 
forms (tablets) were subjected to the analysis of 
their PXT contents by the proposed and the ofﬁ  cial 
[6] methods. The label claim percentage was 
100.2 ± 1.61% (Table 5). This result was compared 
with that obtained from the ofﬁ  cial method by 
statistical analysis with respect to the accuracy 
(by t-test) and precision (by F-test). No signiﬁ  cant 
differences were found between the calculated and 
theoretical values of t- and F-tests at 95% 
conﬁ  dence level proving similar accuracy and 
precision in the determination of PXT by both 
methods.
Because of the high sensitivity of the proposed 
method, it was worthy us to check its applicability 
to the determination of  PXT in spiked human plasma. 
Table 2. Statistical parameters for the determination of 
PXT by the proposed spectroﬂ  uorimetric method based 
on its reaction with NBD-Cl.
Parameter Value
λex (nm) 490
λem (nm) 545
Linear range (ng ml
−1) 80–800
Intercept 5.3550
SD of intercept 1.7646
Slope 0.2304
SD of slope 0.0037
Correlation coefﬁ  cient (r) 0.9993
LOD (ng ml
−1) 25
LOQ (ng ml
−1) 77
formulation. Samples were prepared by mixing 
known amount (20 mg) of PXT with various 
amounts of the common excipients: starch, 
glucose, lactose, acacia, talc, and magnesium 
stearate. These laboratory-prepared samples were 
analyzed by the proposed method applying he 
general 1 procedure. The recovery values were 
98.76–103.02 ± 1.59%–2.15% (Table 4). These 
data conﬁ  rmed the absence of interference from 
any of the common excipients with the determina-
tion of PXT by the proposed spectroﬂ  uorimetric 
method.
Robustness and ruggedness
Robustness was examined by evaluating the inﬂ  u-
ence of small variation in the method variables on 
its analytical performance. In these experiments, 
one parameter was changed whereas the others 
were kept unchanged, and the recovery percentage 
Table 3. Recovery studies for determination of PXT by 
the proposed spectroﬂ  uorimetric method based on its 
reaction with NBD-Cl.
Added (ng ml
−1) Recovery (% ± SD)
a
100 100.2 ± 1.05
150 97.8 ± 1.85
200 99.4 ± 1.28
250 98.4 ± 1.04
300 101.2 ± 1.34
aValues are mean of three determinations.
Table 4. Analysis of PXT in presence of common 
excipients by the proposed spectroﬂ  uorimetric method.
Excipient Recovery (% ± SD)
a
Starch (50)
b 102.36 ± 1.82
Glucose (10) 98.76 ± 1.59
Lactose (10) 99.52 ± 2.04
Acacia (10) 101.49 ± 2.15
Talc (5) 103.02 ± 1.95
MS
c (10) 99.01 ± 1.76
Average ± SD 100.69 ± 1.83
aValues are mean of three determinations.
bFigures in parenthesis are the amounts in mg added per 50 mg of 
PXT.
cMS = Magnesium stearate.154
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Table 5. Analysis of PXT-containing-tablets by the proposed and the ofﬁ  cial methods.
Dosage form
Recovery (% ± RSD)
a
t-value
c F-value
c Proposed Ofﬁ  cial
b
Seroxate tablets 100.2 ± 1.61 99.6 ± 1.22 2.63 1.74
aValues are mean of 5 determinations.
bReference 6.
cThe tabulated values of t- and F- at 95% conﬁ  dence limit are 2.78 and 6.39, respectively
The maximum plasma level of PXT after normal 
daily doses was found to be in the range of 10–30 
ng ml
-1 [23], which could be assessed by the pro-
posed method using small volume (2 ml) of plasma 
samples. The high sensitivity of the proposed 
method allowed the determination of PXT in 
spiked human plasma. The extraction procedure 
described by Zainaghi et al. [9] was adopted here. 
To avoid interferences of water-soluble biogenic 
amines, the extraction procedures should be carried 
out before carrying out the reaction between PXT 
and NBD-Cl. The results were satisfactorily accu-
rate and precise as the recovery was 97.4%–102.2% 
with RSD less than 3% (Table 6).
Conclusions
New spectroﬂ  uorimetric method for the determi-
nation of PXT has been successfully developed 
and validated. The method involved simple 
derivatization of PXT with NBD-Cl reagent, and 
subsequent measuring the ﬂ  uorescence intensity 
of the ﬂ  uorescent reaction product. The proposed 
method is speciﬁ  c, accurate, reproducible, and 
highly sensitive to be applied on the analysis of 
tablets as well as the plasma samples. Furthermore, 
the analysis is relied on a simple apparatus, thus 
the proposed method is suitable for routine 
analysis of PXT in quality control and clinical 
laboratories.
Table 6. Analysis of PXT spiked in plasma samples by 
the proposed spectroﬂ  uorimetric method.
Nominal conc. 
(ng ml
−1)
Measured conc. 
(ng ml
−1)
Recovery 
(% ± RSD)
30 29.4 98.0 ± 2.85
80 77.9 97.4 ± 2.41
120 117.0 97.5 ± 1.85
240 245.2 102.2 ± 2.97
500 490.5 98.1 ± 1.56
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